opt shareholders deserve a conference call, page-34

FFS, sadly its time to move on mate, there is no miracle here, the money on balance sheet will get eaten away and then they will file for bankruptcy.

Lesson with Bio Techs, the best money to be made is on the hype and possibilities.

Less than 10% of biotech startups ultimately succeed in bringing a product to market.

Cumulative probability from pre-clinical to approval: ~10-12%, even for promising drug candidates.


I got lucky on OPT, as I lost $8k on PER and based on that loss I wasn't prepared to risk a possible loss of $130k on OPT and cashed out a couple months after the PER debacle.